{"id":550806,"date":"2021-07-01T15:30:01","date_gmt":"2021-07-01T15:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550806"},"modified":"2021-07-01T15:30:01","modified_gmt":"2021-07-01T15:30:01","slug":"synovial-sarcoma-market-insights-share-size-growth-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-market-insights-share-size-growth-and-market-forecast-2030_550806.html","title":{"rendered":"Synovial Sarcoma Market Insights, Share, Size, Growth and Market Forecast 2030"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625122205.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Synovial Sarcoma Market Insights, Share, Size, Growth and Market Forecast 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625122205.png\" alt=\"Synovial Sarcoma Market Insights, Share, Size, Growth and Market Forecast 2030\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight has added a new research study on <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/synovial-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Synovial Sarcoma Market<\/a><\/strong> Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Synovial Sarcoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8&ndash;10% of all soft tissue sarcomas (STS). Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms but can appear in any part of the body.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Full PDF Sample Copy of Synovial Sarcoma Market Report @ <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/synovial-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/synovial-sarcoma-market<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Synovial Sarcoma Market Regions Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>List of Companies of the Synovial Sarcoma Market Report are- <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>(Trabectadin)<\/li>\n<li>Novartis<\/li>\n<li>Epizyme, Inc.<\/li>\n<li>Adaptimmune<\/li>\n<li>Advenchen Laboratories<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Synovial Sarcoma Causes<\/strong><\/p>\n<p style=\"text-align: justify;\">The exact underlying cause of synovial sarcoma is poorly understood. However, studies indicate that translocation between chromosome X and chromosome 18 appears to play a role in the development of synovial sarcoma. This translocation is specific to synovial sarcoma and is often used to diagnose the condition.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Synovial Sarcoma Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\">In the early stages of the condition, synovial sarcoma may cause no noticeable signs or symptoms but as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit the range of motion or cause numbness and\/or pain if it presses on nearby nerves.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Synovial Sarcoma Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\">The market size of Synovial Sarcoma in seven major markets was estimated at USD 59.43 Million<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/synovial-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Synovial Sarcoma Market<\/a><\/span> Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between&nbsp;SS18&nbsp;and&nbsp;SSX 1, 2,&nbsp;or&nbsp;4. The hybrid transcription factor SS18:SSX alters SWItch\/Sucrose Non-Fermentable (SWI\/SNF) chromatin remodeling and global methylation patterns that may allow future therapeutic opportunities.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/synovial-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Synovial Sarcoma Market<\/a><\/span>: Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">The current treatment of Synovial Sarcoma involves a multimodal approach, incorporating surgery, chemotherapy, and radiotherapy. Currently, surgery remains the mainstay for the treatment of synovial sarcoma. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. However, DelveInsight&rsquo;s market forecast model is based entirely on pharmacological therapies and does not include any procedural or surgical methods.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Read Detailed Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Synovial Sarcoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4. Executive Summary of Synovial Sarcoma<\/p>\n<p style=\"text-align: justify;\">5. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7. Organizations contributing towards Synovial Sarcoma<\/p>\n<p style=\"text-align: justify;\">8. Patient Journey<\/p>\n<p style=\"text-align: justify;\">9. Case Reports<\/p>\n<p style=\"text-align: justify;\">10. Marketed Products<\/p>\n<p style=\"text-align: justify;\">11. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Other Drugs in Development<\/p>\n<p style=\"text-align: justify;\">13. Synovial Sarcoma: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. KOL Views<\/p>\n<p style=\"text-align: justify;\">15. Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">18. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">19. Market Access<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions Answered in <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/synovial-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Synovial Sarcoma Market<\/a><\/span> Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What was the synovial sarcoma market share (%) distribution in 2018, and how would it look in 2030?<\/li>\n<li>What would be the synovial sarcoma total market Size as well as market Size by therapies across the 7MM during the study period (2018&ndash;2030)?<\/li>\n<li>What are the key findings of the market across 7MM, and which country will have the largest Synovial Sarcoma market Size during the study period (2018&ndash;2030)?<\/li>\n<li>At what CAGR, the synovial sarcoma market is expected to grow by 7MM during the study period (2018&ndash;2030)?<\/li>\n<li>What would be the synovial sarcoma market outlook across the 7MM during the study period (2018&ndash;2030)?<\/li>\n<li>What would be the synovial sarcoma market growth till 2030, and what will be the resultant market Size in the year 2030?<\/li>\n<li>How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>How Does This Synovial Sarcoma<\/strong> <strong>Market Insights Help?<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report will help in developing business strategies by understanding trends shaping and driving the synovial sarcoma market.<\/li>\n<li>To understand the future market competition in the synovial sarcoma market and Insightful review of the key market drivers and barriers.<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for synovial sarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/li>\n<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for the synovial sarcoma market.<\/li>\n<li>To understand the future market competition in the synovial sarcoma market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p style=\"text-align: justify;\">We are a business consulting firm with deep industry expertise in life science vertical with core focus on pharma and biotech industries. We consistently help our clients in taking sound decisions facilitating better business performances and achieving incredible growth. Since its inception, DelveInsight has played a pioneering role in providing state of the art services to its clients and prompting informed speculations of the probable prevailing market trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Shruti Thakur<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>info@delveinsight.com<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>USA: +1(919)321-6187<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>India: +91-11-45689769, +91-9650213330<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=synovial-sarcoma-market-insights-share-size-growth-and-market-forecast-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=synovial-sarcoma-market-insights-share-size-growth-and-market-forecast-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has added a new research study on Synovial Sarcoma Market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030 &nbsp; Synovial Sarcoma Overview Synovial &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-market-insights-share-size-growth-and-market-forecast-2030_550806.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-550806","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550806"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}